Neeraj Agarwal, MD, reviews the case of a 73-year-old man with unresectable, locally advanced urothelial carcinoma and discusses latest data and treatment approaches.
Case Overview: A 73-Year-Old Male With Urothelial Carcinoma
Initial presentation
Clinical workup
Treatment
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
October 28th 2024TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
Read More